Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

Biotechnology • Healthcare • Waltham, MA, United States • APGE (NGM)

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
MarketBeat • Jan 2
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Kalkine Media • Jan 2
Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth - Yahoo Finance
Yahoo Finance • Dec 9
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com
Investing.com • Dec 29
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out - Investor's Business Daily
Investor's Business Daily • Oct 9

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Apogee Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Apogee Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Apogee Therapeutics, Inc. have?
Apogee Therapeutics, Inc. has approximately 196 employees.
What industry is Apogee Therapeutics, Inc. in?
Apogee Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Apogee Therapeutics, Inc. a publicly traded company?
Yes, Apogee Therapeutics, Inc. is publicly traded under the ticker symbol APGE on the NGM. The company has a market capitalization of approximately $5.34 billion.
Where is Apogee Therapeutics, Inc. headquartered?
Apogee Therapeutics, Inc. is headquartered in Waltham, MA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.